<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03065998</url>
  </required_header>
  <id_info>
    <org_study_id>066-2017 MOH</org_study_id>
    <nct_id>NCT03065998</nct_id>
  </id_info>
  <brief_title>Double Blind Placebo Control Opipramol-Baclofen Treatment for Addiction</brief_title>
  <official_title>Double Blind Placebo Control Opipramol-Baclofen Treatment for Addiction: Medical and Cognitive Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health, Israel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ministry of Health, Israel</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is examining the combination of two FDA approved drugs, Opipramol and
      baclofen, which may increase rehabilitation from psychoactive substances. Previous studies
      have indicated a connection of sigma-1 receptor to cocaine abuse and raised the possibility
      that these receptors as mediators of drug craving . However previous studies showed partial
      efficacy with no significant relapse in relapse rates. The same is true for the use of
      GABAb-1 receptor antagonist. Opipramol is a selective agonist for sigma-1 receptor. It is
      clinically used as an antidepressant and anxiolytic agent. Moreover, previous open and
      controlled trials indicated that the GABAb-1 antagonist baclofen partial efficacy in
      suppressing withdrawal symptoms in alcohol addicts and cocaine. Our studies in an animal
      model for addiction have shown a significant effect of the combine treatment of the indicated
      medications both in decreasing relapse and increase of -number of respondents.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decreased craving</measure>
    <time_frame>1 month</time_frame>
    <description>Lower withdrawal symptom will be measured by questionnaires</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Drug Abuse</condition>
  <arm_group>
    <arm_group_label>Drug-A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>opripramol 150 mg per day (3*50) Opipramol is a selective agonist for sigma-1 receptor. It is clinically used as an antidepressant and anxiolytic agent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug-B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>baclofen 90 mg per day (3*30) Baclofen is a GABAb-1 antagonist and has shown partial efficacy in suppressing withdrawal symptoms in alcohol addicts and cocaine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opipramol</intervention_name>
    <description>PO</description>
    <arm_group_label>Drug-A</arm_group_label>
    <arm_group_label>Drug-B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baclofen</intervention_name>
    <description>PO</description>
    <arm_group_label>Drug-A</arm_group_label>
    <arm_group_label>Drug-B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age will be 60-18, both sexes, seeking treatment in order to stop the consumption of
             materials

        Exclusion Criteria:

          -  Did not include trial addicts with co-morbidity, kidney, heart, metabolic,
             neurological and psychiatric disorders (psychosis, chronic depression).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gal Yadid, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bar Ilan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Roska, MD</last_name>
    <phone>972-2-5080645</phone>
    <email>paola.roska@MOH.GOV.IL</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keren Goldman, MsC</last_name>
    <phone>972-2-5080650</phone>
    <email>keren.goldman@moh.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Retorno rehabilitation center</name>
      <address>
        <city>Bet Shemesh</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eitan Eckstein</last_name>
      <phone>9-73-210439</phone>
      <email>eitan@retorno.org</email>
    </contact>
    <contact_backup>
      <last_name>Shira Eckstein</last_name>
      <phone>972-2-5318123</phone>
      <email>shiraeckbiu@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2017</study_first_submitted>
  <study_first_submitted_qc>February 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2017</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opipramol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

